Navigation Links
BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
Date:6/7/2011

RALEIGH, N.C., June 7, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Jeffries Global Healthcare Conference at the Grand Hyatt, New York City.  The presentation is scheduled for Thursday, June 9 at 3:00 P.M. Eastern Time.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

Dr. Sirgo will focus on BDSI's product pipeline, with a particular focus on BEMA Buprenorphine for the treatment of chronic pain and opioid dependence.  

The presentation will be made available at www.bdsi.com.  

About BioDelivery Sciences International

BioDelivery Sciences International (Nasdaq: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, results of the clinical development for and regulatory review of the Company's product candidates) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, ... continuation of its strategic partnership with and platinum sponsorship of Global Spine Outreach ... safe and effective management of complex spine deformity cases, particularly in children. , ...
(Date:4/24/2017)... ... 2017 , ... Michael Vick announced his retirement earlier this year from the ... number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made four ... most career rushing yards by a quarterback (6,109) and the most rushing yards by ...
(Date:4/24/2017)... ... 24, 2017 , ... As part of the nationwide Days of Remembrance effort ... the Holocaust and Nazi persecution, Center for Medicine after the Holocaust (CMATH) ... Champions trip to Germany and Poland next week. , The Fourth Biennial CMATH Champions ...
(Date:4/24/2017)... ... 2017 , ... Today, Bright Pink , a national non-profit organization focusing on the prevention ... , Bright Pink is proud to announce Katie Thiede as their new Chief Executive ... role as Chairman of the Board and launched a national search to find a ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):